{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Harrell CR"],"funding":["Faculty of Medical Sciences University of Kragujevac","Swiss National Science Foundation"],"pagination":["1939768"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7678745"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["2020"],"pubmed_abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent responsible for the development of a new coronavirus disease (COVID-19), is a highly transmittable virus which, in just ten months, infected more than 40 million people in 214 countries worldwide. After inhalation, aerosols containing SARS-CoV-2 penetrate to the depths of the lungs and cause severe pneumonia, alveolar injury, and life-threatening acute respiratory distress syndrome (ARDS). Since there are no specific drugs or vaccines available to cure or prevent COVID-19 infection and COVID-19-related ARDS, a new therapeutic agent which will support oxygen supply and, at the same time, efficiently alleviate SARS-CoV-2-induced lung inflammation is urgently needed. Due to their potent immuno- and angiomodula"],"journal":["Analytical cellular pathology (Amsterdam)"],"pubmed_title":["Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome."],"pmcid":["PMC7678745"],"funding_grant_id":["185546","ON175069","ON175103","MP01/18","IZSEZ0 185546"],"pubmed_authors":["Djonov V","Volarevic V","Harrell CR","Jovicic BP"],"additional_accession":[]},"is_claimable":false,"name":"Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome.","description":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent responsible for the development of a new coronavirus disease (COVID-19), is a highly transmittable virus which, in just ten months, infected more than 40 million people in 214 countries worldwide. After inhalation, aerosols containing SARS-CoV-2 penetrate to the depths of the lungs and cause severe pneumonia, alveolar injury, and life-threatening acute respiratory distress syndrome (ARDS). Since there are no specific drugs or vaccines available to cure or prevent COVID-19 infection and COVID-19-related ARDS, a new therapeutic agent which will support oxygen supply and, at the same time, efficiently alleviate SARS-CoV-2-induced lung inflammation is urgently needed. Due to their potent immuno- and angiomodula","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020","modification":"2025-05-29T20:19:42.084Z","creation":"2025-05-29T20:19:42.084Z"},"accession":"S-EPMC7678745","cross_references":{"pubmed":["33274176"],"doi":["10.1155/2020/1939768"]}}